Mesoblast Biotechnology Company has received FDA approval for its Ryoncil therapy as the first of its kind to be approved in the United States.
The therapy has been developed to treat steroid-refractory acute graft-versus host-disease (SR-aGVHD) in adults and in babies and children who are over two months. The FDA’s decision thrusts Ryoncil into prominence as the first mesenchymal stromal cell therapy to receive such approval.
Note that aGVHD is life-threatening. It may occur if a patient’s aGVHD is not responsive to steroids.
About Ryoncil
Ryoncil, an allogeneic (of the same species) therapy, contains mesenchymal stromal cells that can develop into many other cell types. The bone marrow of healthy individuals is used for the transplants.
The FDA’s director for Biologics, Peter Marks, noted that this specific approval is evidence of the FDA’s support for the development of products for patients with symptoms that have not responded to other treatments.
SR-aGVHD occurs to approximately fifty percent of patients who undergo bone marrow transplants as the blood marrow of the donor reacts negatively to its host.
Thus far patients have relied on first-line treatment with systemic steroids but almost fifty percent of these patients do not respond to treatment (refractory) thereby increasing mortality rates.
Nicole Verdun, CBER’s director of Therapeutic Products joined director Marks in concern regarding the damage to organs and risk of death.
An Improved Response
Ryoncil’s FDA approval was based on results from a phase III clinical trial that involved 54 pediatric patients who had SR-aGVHD. The participants received four weeks of treatment with Ryoncil infused intravenously twice weekly.
Results showed that thirty percent of recipients had a complete response while forty-one patients had a partial response.
Ryoncil’s changes to the body’s immune system include inhibiting T cells and the secretion of pro-inflammatory cytokines. The company added that Ryoncil also has the potential to treat heart failure and pain in the lower back.
The treating physician is to monitor the infusions and discontinue treatment if certain reactions are observed such as skin discoloration or rapid breathing.
Study Reactions
Several adverse reactions experienced by study participants receiving Ryoncil infusions were edema, fever, hypertension, and adnominal pain.
Other complications such as reactions to infusions or infectious disease agents may occur after Ryoncil treatment.
See additional information with regard to hypersensitivity and premedication here.
Source: Home – Mesoblast Ltd
